Akeso's 2024 Results Conference Call: Insights and Updates

Author: Hannah Lewis Updated: 03-28-2025 12:40 PM

Akeso's Upcoming 2024 Financial Results Conference Call

Akeso Inc. (9926.HK) is gearing up to hold an important conference call that will cover its final financial results for the year 2024. This call is scheduled for March 31, and it promises to provide valuable insights into the company's performance over the year and a glimpse into what the future may hold.

Conference Call Timing and Participation

The call will occur at various times across key global locations. For those in Hong Kong and Singapore, it will run from 20:00 to 21:00. In London, the session will start at 13:00 and for those in New York, it will take place from 08:00 to 09:00. Investors and other stakeholders are encouraged to participate, as the management team will address burning questions and share crucial information.

Key Management Presenting

Notable figures from Akeso's executive team will present during this call. Key attendees will include Dr. Michelle Xia, the Chairwoman, President & CEO, along with Dr. Baiyong Li, the Chief Scientific Officer, and Dr. Bing C. Wang, the Chief Financial Officer. They will work together to give an overview of the company's financial landscape, discussing not only outcomes but also expectations for 2025.

Innovative Pipeline Insights

During the call, the management team will dive deep into Akeso's innovative pipeline. This discussion will focus on recent developments and the progress of significant therapies that the company has in the works. They will highlight advancements in bispecific antibodies like cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF). Additionally, updates regarding the CD47 monoclonal antibody, antibody-drug conjugates (ADCs), and bispecific ADCs are on the agenda.

About Akeso

Founded in 2012, Akeso has quickly risen to become a frontrunner in the biopharmaceutical industry. The company is dedicated to the development, manufacturing, and commercialization of innovative biological medicines, striving to deliver groundbreaking solutions in healthcare. Their research and development ecosystem, particularly the ACE Platform, comprises an end-to-end drug development approach that optimally supports the advancement of over 50 innovative therapeutic assets across various significant diseases, including cancer, autoimmune diseases, and metabolic disorders.

As of now, Akeso has 23 candidates in clinical trials, including a number of bispecific/multispecific antibodies and ADCs. Furthermore, the company boasts six new drugs that are commercially available, alongside five additional drugs currently undergoing regulatory review for approval across seven indications. Akeso's mission remains to integrate superior global resources to create first-in-class and best-in-class drugs, ensuring availability and affordability for patients worldwide.

Frequently Asked Questions

1. What date is the Akeso conference call scheduled for?

The conference call is scheduled for March 31, 2025.

2. Who will be presenting during the call?

The call will feature Dr. Michelle Xia, Dr. Baiyong Li, and Dr. Bing C. Wang from Akeso's management team.

3. What topics will be discussed during the call?

The call will cover the financial results of 2024, insights into the innovative pipeline, and future strategic directions of the company.

4. How can investors participate in the call?

Investors can participate by pre-registering for the call. They may also contact their Morgan Stanley sales representative for further details.

5. What is Akeso's focus in the biopharmaceutical industry?

Akeso focuses on the research and development of innovative biological medicines, primarily in the fields of cancer and other significant diseases.

About The Author

Hi there, I'm Hannah Lewis, a writer and financial specialist of 36 years old committed to making money understandable and approachable to everyone. Years of working in the field have given me a thorough grasp of market trends, investment techniques, and economic fundamentals. My objective is to enable people, by means of understandable, useful guidance, to take charge of their financial destiny.

I have written many articles for financial blogs over my career that simplify difficult financial ideas into understandable insights. Being financially literate is a critical ability, and I am passionate about enabling people to confidently manage their financial lives. Regardless of your level of experience, my work will help you at every stage of the investment process. I appreciate being allowed to share in your success and financial expansion.

Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.